HIF1A and cancer: Depleting GSH sensitizes cancer cells to CuO2/DDP@SiO2-induced cuproptosis, causing lipoylated mitochondrial protein aggregation. In vitro, reduced GSH binding boosts intracellular cisplatin levels. CuO2 down-regulates MRP2 via O2-dependent HIF-1 inactivation, blocking cisplatin efflux and enhancing its anticancer effect both in vitro and in vivo.